RapidAI announced recently that its combined haemorrhagic solution—Rapid ICH (intracranial haemorrhage) and Rapid Hyperdensity—has been selected as the “Best New Imaging Solution” in the seventh annual MedTech Breakthrough Awards, which attracted more than 4,000 nominations from over 17 countries this year.
RapidAI was chosen for its solution’s meaningful impact on the treatment of acute haemorrhagic stroke and head trauma care in hospitals around the world, a press release from the company states.
When it comes to brain haemorrhage, speed and accuracy in diagnosis are “essential”, the release continues, and Rapid ICH and Rapid Hyperdensity use artificial intelligence (AI) to quickly assess non-contrast computed tomography (NCCT) scans for suspected haemorrhage and automatically calculate the hyperdense volume output in minutes.
For hospitals and mobile stroke units on the front lines of patient assessment, this additional contextual data is critical to helping them make faster, more informed triage and transfer decisions, RapidAI also claims.
“We are thrilled to receive the MedTech Breakthrough award in recognition of our efforts to revolutionise care for haemorrhagic stroke patients,” said Karim Karti, CEO of RapidAI. “We have accomplished so much in the past year—including several FDA [Food and Drug Administration] 510(k) clearances, crossing the 10 million patient scans milestone, and several awards—but this is only the beginning. I am incredibly proud of the impact the team has made, and look forward to our continued game-changing innovation in the treatment of vascular and neurovascular conditions.”